Obesity is one of the fastest-growing health problems in the world. It raises the risk of heart disease, type 2 diabetes, fatty liver disease, high blood pressure, stroke, and several types of cancer.
Although healthy eating and regular exercise are still the foundation of weight management, many people find it very difficult to lose weight and keep it off over the long term.
Scientists are therefore searching for new medicines that target the biological causes of obesity. Researchers at Johns Hopkins Medicine have now discovered that a drug originally developed for other diseases may offer a completely new way to fight excess weight. Their findings were published in the Journal of Clinical Investigation.
The medicine works by blocking an enzyme called PDE9. Enzymes are proteins that help control many chemical reactions inside the body. Earlier studies showed that PDE9 affects heart function, leading researchers to wonder whether it might also influence metabolism and body fat.
The research team had first identified the role of PDE9 in heart disease several years ago. They found that the enzyme could worsen heart problems, particularly in people with high blood pressure. This prompted them to investigate whether blocking PDE9 could improve other conditions that often occur alongside obesity.
In the new study, the scientists tested an experimental drug called PF-04447943 in mice. The medicine had originally been created by Pfizer to treat Alzheimer’s disease. Although it was not effective for Alzheimer’s, previous human safety studies involving more than 100 volunteers found no serious side effects.
The results in mice were encouraging. Animals treated with the drug gained less body fat, had healthier livers, improved heart function, and lower levels of harmful blood fats. Remarkably, these improvements occurred without the mice eating less food or exercising more.
The researchers also found benefits for blood sugar control and other measures linked to metabolic health. These findings suggest that PDE9 may influence how the body stores and uses energy rather than simply affecting appetite. This challenges the traditional view that obesity is caused only by eating too much.
The experimental medicine belongs to a group of drugs known as PDE9 inhibitors. They work in a similar way to Viagra, which blocks a different enzyme called PDE5. Both enzymes help regulate a chemical messenger called cyclic GMP, which is involved in many important body processes.
Although the findings are exciting, they do not mean people will soon have a pill that replaces healthy eating and exercise. The current results come from animal studies, and medicines often behave differently in humans. Researchers must now carry out larger clinical trials to determine whether the drug is effective and safe for long-term treatment of obesity.
If future human studies confirm these early results, PDE9 inhibitors could become an important new option for people living with obesity, especially those who have struggled despite making lifestyle changes. The discovery also highlights that body weight is influenced by complex biological processes, opening the door to more targeted treatments in the future.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about ginger’s journey in weight management ,and green tea: a cup of weight loss.
Copyright © 2026 Knowridge Science Report. All rights reserved.
